MIGA2

Across TCGA pan-cancer cohorts, MIGA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MIGA2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MIGA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIGA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where MIGA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.832	0.615	.026	8	view →
PDAC	DFS	Quartile	II,III,IV	0.915	0.430	.024	3	view →
UCEC	DFS	Median	All	0.911	1.000	.038	2	view →
HNSC	DFS	Quartile	All	0.905	1.000	.014	2	view →
LUAD	DFS	Quartile	All	0.335	0.720	.028	2	view →
LSCC	OS	Median	All	0.773	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MIGA2–CCRCC (DFS)

Open the CCRCC breakdown →